Email updates

Keep up to date with the latest news and content from Nutrition Journal and BioMed Central.

Open Access Research

Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study

Zhaoping Li*, Hannah Karp, Alona Zerlin, Tsz Ying Amy Lee, Catherine Carpenter and David Heber

Author affiliations

Center for Human Nutrition, University of California Los Angeles, Los Angeles, CA, USA

For all author emails, please log on.

Citation and License

Nutrition Journal 2010, 9:44  doi:10.1186/1475-2891-9-44

The electronic version of this article is the complete one and can be found online at: http://www.nutritionj.com/content/9/1/44


Received:27 April 2010
Accepted:14 October 2010
Published:14 October 2010

© 2010 Li et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Decreased bone mineral density and osteoporosis in postmenopausal women represents a growing source of physical limitations and financial concerns in our aging population. While appropriate medical treatments such as bisphosphonate drugs and hormone replacement therapy exist, they are associated with serious side effects such as osteonecrosis of the jaw or increased cardiovascular risk. In addition to calcium and vitamin D supplementation, previous studies have demonstrated a beneficial effect of dietary silicon on bone health. This study evaluated the absorption of silicon from bottled artesian aquifer water and its effect on markers of bone metabolism.

Methods

Seventeen postmenopausal women with low bone mass, but without osteopenia or osteoporosis as determined by dual x-ray absorptiometry (DEXA) were randomized to drink one liter daily of either purified water of low-silicon content (PW) or silicon-rich artesian aquifer water (SW) (86 mg/L silica) for 12 weeks. Urinary silicon and serum markers of bone metabolism were measured at baseline and after 12 weeks and analyzed with two-sided t-tests with p < 0.05 defined as significant.

Results

The urinary silicon level increased significantly from 0.016 ± 0.010 mg/mg creatinine at baseline to 0.037 ± 0.014 mg/mg creatinine at week 12 in the SW group (p = 0.003), but there was no change for the PW group (0.010 ± 0.004 mg/mg creatinine at baseline vs. 0.009 ± 0.006 mg/mg creatinine at week 12, p = 0.679). The urinary silicon for the SW group was significantly higher in the silicon-rich water group compared to the purified water group (p < 0.01). NTx, a urinary marker of bone resorption did not change during the study and was not affected by the silicon water supplementation. No significant change was observed in the serum markers of bone formation compared to baseline measurements for either group.

Conclusions

These findings indicate that bottled water from artesian aquifers is a safe and effective way of providing easily absorbed dietary silicon to the body. Although the silicon did not affect bone turnover markers in the short-term, the mineral's potential as an alternative prevention or treatment to drug therapy for osteoporosis warrants further longer-term investigation in the future.

Trial Registration

ClinicalTrials.gov Identifier: NCT01067508

Background

Osteoporosis is a leading cause of morbidity and mortality in the elderly [1]. In the U.S., an estimated 4-6 million women aged >50 years have osteoporosis, and another 13-17 million (37%-50%) have osteopenia (or low bone density) based on femoral bone mineral density (BMD) tests using dual x-ray absorptiometry (DEXA) when osteoporosis is defined by a T-score of less than -2 while osteopenia is defined as having a T-score between -2 and -1.5 [1]. As a result of demographic shifts and an aging population in the U.S. there has been a significant increase in the number of adults with low femoral neck BMD (osteoporosis + osteopenia) in 2005-2006 compared to the number identified between 1988 and1994 [2]. Osteoporosis causes 1.5 million fractures in the U.S. annually, including 300,000 hip fractures and 700,000 vertebral spine fractures [3]. The estimated cost of treating osteoporotic fractures in 2005 was $17 billion, and this cost is expected to increase by 50% by 2025 as the population ages [4].

Beyond genetic and hormonal factors that affect bone density with aging, lifestyle factors including inadequate intake of calcium and vitamin D, smoking, excessive alcohol use, regular consumption of soft drinks, lack of physical exercise, and lack of fruit and vegetable intake exacerbate decreases in bone density which increase the risk for bone fracture [5-8]. Clinicians commonly recommend calcium and vitamin D supplementation, bisphosphonate drugs, strontium ranelate, calcitonin, parathyroid hormone, estrogen, and some anti-estrogens with weak estrogen effects to women with reduced bone density in order to reduce bone turnover, but have paid less attention to nutritional factors such as reducing soft drink consumption [9]. While appropriate for treating osteoporosis, these medical approaches have been associated with serious side effects such as osteonecrosis of the jaw in patients receiving oral bisphosphonates [10], and increased risks of breast cancer, stroke, and venous thromboembolism in women treated with postmenopausal hormone replacement therapy [11].

Silicon (Si) is the most abundant trace element in the diet after iron and zinc. In 1970, Carlisle suggested that silicon is a possible factor in bone calcification [12]. The dietary consumption of silicon and other trace minerals has been associated positively with bone mass, while mineral deficiencies have been associated with reduced bone density [13,14]. Animal studies in the 1970's reported that dietary silicon deficiency resulted in reduced bone tensile strength [15,16]. In the Framingham offspring cohort, increased dietary silicon intake was associated with increased bone mass [17].

Drinking water and other fluids provide a significant potential dietary source of silicon, since silicon is primarily present in water as Si(OH)4 [18]. Bottled water from artesian aquifers contains silicon obtained from volcanic rock while typical bottled water, an increasingly popular alternative to soft drinks, is purified through reverse osmosis and does not contain significant amounts of any trace minerals. In comparison with the silicon-rich water which contains 85 to 90 mg/L silica, the purified water contains undetectable amount of silica. Beer contains 0.9 to 3.94 mg silicon/100 gram and is another potentially beneficial source of silicon for healthy bone [19]. However, heavy beer drinking is associated with a reduced trabecular bone density in the spine [20]. Water originating from artesian aquifers represents a good source of dietary silicon, without the disadvantages arising from increased consumption of beer. The present study was carried out in postmenopausal women with reduced bone density confirmed by DEXA in order to determine the absorption of silicon from artesian drinking water and its effects on bone remodeling markers as assessed by accepted metabolic markers in addition to calcium and vitamin D supplementation..

Methods

Subjects

Postmenopausal women within 5 years of menopause were recruited into the study. They were required to have reduced bone density but no evidence of osteoporosis or osteopenia by DEXA scan (T ≥ -1.5 in the total hip and lumbar spine). Women with a body mass index (BMI) >30 kg/m2 or who were being treated with estrogens, corticosteroids, or bisphosphonates, who consumed more than one alcoholic beverage a day, or who had significant illness affecting bone metabolism were excluded.

The study protocol was approved by the Institutional Review Board at the University of California, Los Angeles (UCLA) and was conducted at the UCLA Center for Human Nutrition. All subjects gave written informed consent prior to participation in the study. All study methods and procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki and Good Clinical Practice Guidelines.

Study Design

This was a 12 week, randomized, placebo-controlled, interventional study. Subjects who met the inclusion and exclusion criteria were instructed to take 1200 mg of calcium and 800 IU of vitamin D (Caltrate 600+D Calcium Supplement, Wyeth Consumer Healthcare, Madison, NJ, USA) daily during a two week run-in and to continue this supplementation throughout the study. At baseline, subjects were randomized either to the silicon-rich water group (SW) or the purified water group of low-silicon content (PW). The SW group received bottled FIJI Water® (FIJI Water LLC, Los Angeles, CA, USA) and the PW group received purified bottled water (Aguafina® water, Pepsico, Inc.). Subjects were instructed to drink one liter of study provided water daily directly from the bottle. New batch of water was dispensed and empty water bottles were collected every 4 weeks to ensure compliance with the protocol. Subjects were instructed not to alter their activity level or diets in any way outside of consuming the water and supplements provided to them by the study.

Measurements

A basic clinical examination including measurement of body weight, systolic and diastolic blood pressure and heart rate was performed at screening, baseline visit and week 12. All subjects were instructed to fast overnight 10 hours prior to their clinic visits. Fasting blood samples (18 ml per time point) and fasting single void, midstream spot urine samples were collected at screening, baseline and week 12 during morning appointments. The blood samples were measured for 25-hydroxy vitamin D, parathyroid hormone (PTH), procollagen type I intact N-terminal propeptide, bone specific alkaline phosphatase and osteocalcin; urine samples were analyzed for silicon, creatinine, calcium and collagen type 1 cross-linked N-telopeptide (NTx).

Urine silicon concentration was measured by NMS Labs (Willow Grove, PA, USA) using inductively coupled plasma atomic emission spectroscopy (ICP-AES). The calibration range is from 1 to 10 mcg/L with two urine controls at 4 and 10 mg/L. These were prepared using a 10 mg/mL solution of silicone in water with 0.4% F-. The %CV for the low control was 6.4 and for the high control was 5.2. All the other blood and urine samples were analyzed by the Ronald Reagan UCLA Medical Center Clinical Laboratory (CLIA and CAP certified) using commercially available kits.

Statistical analysis

Results are expressed as means ± standard deviation (SD). Differences between the two groups were evaluated with t-tests. All tests are two-sided and p < 0.05 was defined as significant.

Results

Bottled waters

The silica content in the bottled water was measured at MWH Laboratories (Monrovia, California, USA) by the method of EPA 200.7-ICP and the test results met all NELAC (National Environmental Laboratory Accreditation Conference) requirements. The silicon-rich water contained 86 mg/L of silica while the purified bottled water contained no detectable amount.

Subjects

41 post-menopausal women with reduced bone density were screened for the study. Twenty-two subjects did not meet the inclusion criteria and were excluded from participation. Two subjects withdrew from the study after the baseline visit, one due to time constraints and the other at the request of the investigator concerning for her cardiovascular health. The remaining 17 women completed the study. Both PW and SW were well tolerated without adverse events.

The average age was 54 years, BMI of 24.1 kg/m2 and a t-score of -0.45 in the hip and -0.3 in the spine by DEXA. Both groups were well matched in age, BMI and bone density (Table 1). There were more White women in the SW and more Asian women in PW groups.

Table 1. Baseline characteristics of study subjects

Urinary silicon

The urinary creatinine was compatible between the groups at baseline (82.2 ± 46.6 mg/dL in PW vs. 78.8 ± 43.2 mg/dL in SW groups) and there was not any significant change within groups during the study (p = 0.878). The screening urinary silicon was 0.012 ± 0.008 mg/mg creatinine in SW group and 0.012 ± 0.008 mg/mg creatinine in PW group, obtained from a fasting single spot collection. There was a decrease of silicon between screen and baseline for the PW group but was not statistically significant. The urinary silicon level increased significantly from 0.016 ± 0.010 mg/mg creatinine at baseline to 0.037 ± 0.014 mg/mg creatinine at week 12 in the SW group (p = 0.003), but there was no change for the PW group (0.010 ± 0.004 mg/mg creatinine at baseline vs. 0.009 ± 0.006 mg/mg creatinine at week 12, p = 0.679). At the end of the study, the urinary silicon for the SW group increased by 133.5% which was a statistically significant increase by comparison to the PW group (p < 0.01) (Figure 1).

thumbnailFigure 1. Urine silicon. Mean ± SD. Fasting spot urine was collected for urine creatinine and silicon. *silicon increased significantly (p < 0.05) in the silicon-rich water group from baseline to Week 12. No change was seen for the purified water group.

Urinary N-telopeptide

Urinary collagen type 1 cross-linked N-telopeptide excretion was normalized to creatinine in a fasting spot urine sample as a reflection of daily NTx. There was not any significant difference for baseline NTx levels between the two groups (36.0 ± 18.0 nmol/mmol in SW vs. 27.2 ± 11.5 nmol/mmol creatinine in PW). At the end of the study, differences between the groups were insignificant (36.0 ± 17.4 nmol/mmol in SW vs. 27.4 ± 8.1 nmol/mmol in PW, p = 0.250). There was not any statistic difference within groups either.

Serum bone turnover markers

All the subjects had normal calcium levels during the entire study. One subject in the PW group had low vitamin D 25-hydroxy level (15 ng/ml) in spite of vitamin D supplementation. Baseline bone metabolism marker levels were not significantly different between groups. There as a wide variation in bone marker level in both groups at baseline and week 12. There was no change of parathyroid hormone or markers of bone formation including procollagen type I intact, N-terminal propeptide, bone specific alkaline phosphatase, and osteocalcin within groups or between groups (Table 2).

Table 2. Serum bone turnover markers

Discussion

Since the silicon deprivation studies [15,16] that suggested a potential role of silicon in bone and connective tissue health, there have been many studies investigating the potential role of dietary silicon in bone health [21]. Schiano et al reported that supplementation with soluble salt of silicium resulted in a significant increase in the total bone volume both in drinkable and in injectable form [22]. In a later study, silicon was shown to be more effective than Etidronate and sodium fluoride over a 14 to 22 month period [23]. In a recent double blind, placebo-controlled 12 month trial in osteopenic and osteoporotic subjects, Spector et al [24] reported that oral choline-stabilized orthosilicic acid had potential beneficial effects on bone collagen and a trend for a dose-related decrease in the bone resorption marker, collagen type 1 C-terminal telopeptide at 6 and 12 months.

The primary aim of the present study was to investigate the absorption of bottled silicon water. As much as 50% of ingested silicon is excreted in the urine [25]. Urinary excretion of silicon is a good marker of absorbed silicon and correlates well with dietary intake of silicon [19]. We clearly demonstrated that 86 mg/day of silica provided with bottled water significantly increased the urinary excretion of silicon.

The main route of entry of silicon to the body is from the gastrointestinal tract. Gastrointestinal uptake of silicon from foods was estimated in women as 24 mg/day and men as 30 mg per day. The major food sources are beer and bananas in men, and bananas and string beans in women [26]. It should be noted, however, that higher intakes of alcohol are associated with reduced bone density. Foods can be a major source of silicon [27,28], but in our study the intake of silicon-rich water from an artesian aquifer significantly increased silicon excretion over what was being excreted from dietary sources. Asians and Indians have much higher silicon intakes than do Western populations [29,30], and also have a lower incidence of hip fracture [31]. In addition, silicon intake decreases with age, with an average 0.1 mg less for every additional year of age [26]. Bottled silicon-rich water can be an additional source to improve silicon intake.

The present study did not demonstrate any significant change of bone metabolism markers in 12 weeks. All the study subjects were postmenopausal women. In the Framingham offspring cohort study Jugdaohsingh et al found that silicon intake was positively associated with bone mineral density for men and premenopausal women but not for postmenopausal women [17]. Men or premenopausal women may respond to silicon rich water differently. In the osteoporosis drug treatment studies the bone metabolism markers are mostly measured no earlier than 6 month [32-34]. This study was only 12 weeks. A longer supplementation period or lower BMD group may therefore have shown a greater effect of Si. It has been previously suggested that the effect of silicon is best under low calcium intake. Indeed a recent study by Kim et al [35] reported that Si supplementation increased bone mineral density in ovariectomised rats, only when the feed was deficient in calcium. No effect was seen under calcium replete or high calcium intake group. Finally change of short-term markers of bone resorption may not be the only mechanisms by which silicon improves bone health.

There have been conflicting reports on the influence of calcium and vitamin D on bone metabolic markers demonstrating no effect on markers of bone turnover but effects on bone loss [36,37]. To eliminate the potential effects of vitamin D and calcium deficiency on bone markers, all subjects in the present study were supplemented with vitamin D and calcium. We did not see any additional benefit of silicon supplementation on short-term markers of bone remodeling over 12 weeks.

Further research including studies over several years examining changes in bone density following long-term daily consumption of silicon-rich water obtained from artesian aquifers in women with reduced bone density are needed.

Conclusions

This study clearly demonstrated that 86 mg/day of silica from bottled water increased urinary excretion of silicon over a 12-week period in post-menopausal women. This indicates that artesian aquifer bottled water is a safe and effective way of providing easily absorbed dietary silicon to the body. Although the silicon did not affect bone turnover in the short-term, the mineral's potential as an alternative prevention or treatment to drug therapy for osteoporosis warrants further, longer-term investigation in the future.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ZL conceived of the study, participated in its design and coordination, performed statistical analysis, and draft the manuscript. HK coordinated the study and helped to draft the manuscript. AZ provided the dietary counsel for the study. TYL participated in subject screening and assessment. CC participated in subject assessment and assisted with statistical analysis. DH conceived of the study and helped draft the manuscript. All authors read and approved the final manuscript

Acknowledgements

This study is supported by the Department of Medicine, David Geffen School of Medicine. The Fiji water was donated by FIJI Water LLC, Los Angeles, CA, USA.

References

  1. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, et al.: Prevalence of low femoral bone density in older U.S. adults from NHANES III.

    J Bone Miner Res 1997, 12:1761-68. PubMed Abstract | Publisher Full Text OpenURL

  2. Looker AC, Melton LJ, Harris TB, Borrud LG, Shepherd JA: Prevalence and Trends in Low Femur Bone Density Among Older US Adults: NHANES 2005-2006 Compared with NHANES III.

    J Bone Miner Res 2010, 25:64-71. PubMed Abstract | Publisher Full Text OpenURL

  3. Riggs BL, Melton LJ: The worldwide problem of osteoporosis: insights afforded by epidemiology.

    Bone 1995, 17:505S-11S. PubMed Abstract | Publisher Full Text OpenURL

  4. Burge R, wson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

    J Bone Miner Res 2007, 22:465-75. PubMed Abstract | Publisher Full Text OpenURL

  5. Kohrt WM, Bloomfield SA, Little KD, Nelson ME, Yingling VR: American College of Sports Medicine Position Stand: physical activity and bone health.

    Med Sci Sports Exerc 2004, 36:1985-96. PubMed Abstract | Publisher Full Text OpenURL

  6. Eisman JA: Genetics, calcium intake and osteoporosis.

    Proc Nutr Soc 1998, 57:187-93. PubMed Abstract | Publisher Full Text OpenURL

  7. Reid DM, New SA: Nutritional influences on bone mass.

    Proc Nutr Soc 1997, 56:977-87. PubMed Abstract | Publisher Full Text OpenURL

  8. Tucker KL: Osteoporosis prevention and nutrition.

    Curr Osteoporos Rep 2009, 7:111-17. PubMed Abstract | Publisher Full Text OpenURL

  9. Stevenson M, Jones ML, De NE, Brewer N, Davis S, Oakley J: A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

    Health Technol Assess 2005, 9:1-160. PubMed Abstract | Publisher Full Text OpenURL

  10. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P: A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.

    Clin Ther 2007, 29:1548-58. PubMed Abstract | Publisher Full Text OpenURL

  11. Banks E, Canfell K: Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.

    Am J Epidemiol 2009, 170:24-28. PubMed Abstract | Publisher Full Text OpenURL

  12. Carlisle EM: Silicon: a possible factor in bone calcification.

    Science 1970, 167:279-80. PubMed Abstract | Publisher Full Text OpenURL

  13. Tucker KL: Osteoporosis prevention and nutrition.

    Curr Osteoporos Rep 2009, 7:111-17. PubMed Abstract | Publisher Full Text OpenURL

  14. Palacios C: The role of nutrients in bone health, from A to Z.

    Crit Rev Food Sci Nutr 2006, 46:621-28. PubMed Abstract | Publisher Full Text OpenURL

  15. Carlisle EM: Silicon: an essential element for the chick.

    Science 1972, 178:619-21. PubMed Abstract | Publisher Full Text OpenURL

  16. Schwarz K, Milne DB: Growth-promoting effects of silicon in rats.

    Nature 1972, 239:333-34. PubMed Abstract | Publisher Full Text OpenURL

  17. Jugdaohsingh R, Tucker KL, Qiao N, Cupples LA, Kiel DP, Powell JJ: Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the Framingham Offspring cohort.

    J Bone Miner Res 2004, 19:297-307. PubMed Abstract | Publisher Full Text OpenURL

  18. Bellia JP, Birchall JD, Roberts NB: Beer: a dietary source of silicon.

    Lancet 1994, 343:235. PubMed Abstract | Publisher Full Text OpenURL

  19. Sripanyakorn S, Jugdaohsingh R, Dissayabutr W, Anderson SH, Thompson RP, Powell JJ: The comparative absorption of silicon from different foods and food supplements.

    Br J Nutr 2009, 102:825-34. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  20. Tucker KL, Jugdaohsingh R, Powell JJ, Qiao N, Hannan MT, Sripanyakorn S, et al.: Effects of beer, wine, and liquor intakes on bone mineral density in older men and women.

    Am J Clin Nutr 2009, 89:1188-96. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  21. Jugdaohsingh R: Silicon and bone health.

    J Nutr Health Aging 2007, 11:99-110. PubMed Abstract | PubMed Central Full Text OpenURL

  22. Schiano A, Eisinger F, Detolle P, Laponche AM, Brisou B, Eisinger J: Silicon, bone tissue and immunity.

    Rev Rhum Mal Osteoartic 1979, 46:483-86. PubMed Abstract OpenURL

  23. Eisinger J, Clairet D: Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study.

    Magnes Res 1993, 6:247-49. PubMed Abstract OpenURL

  24. Spector TD, Calomme MR, Anderson SH, Clement G, Bevan L, Demeester N, et al.: Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone formation in osteopenic females: a randomized, placebo-controlled trial.

    BMC Musculoskelet Disord 2008, 9:85. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  25. Kelsay JL, Behall KM, Prather ES: Effect of fiber from fruits and vegetables on metabolic responses of human subjects, II. Calcium, magnesium, iron, and silicon balances.

    Am J Clin Nutr 1979, 32:1876-80. PubMed Abstract | Publisher Full Text OpenURL

  26. Jugdaohsingh R, Anderson SH, Tucker KL, Elliott H, Kiel DP, Thompson RP, et al.: Dietary silicon intake and absorption.

    Am J Clin Nutr 2002, 75:887-93. PubMed Abstract | Publisher Full Text OpenURL

  27. Robberecht H, Van CR, Van VV, Hermans N: Dietary silicon intake in Belgium: Sources, availability from foods, and human serum levels.

    Sci Total Environ 2009, 407:4777-82. PubMed Abstract | Publisher Full Text OpenURL

  28. Pennington JA: Silicon in foods and diets.

    Food Addit Contam 1991, 8:97-118. PubMed Abstract OpenURL

  29. Anasuya A, Bapurao S, Paranjape PK: Fluoride and silicon intake in normal and endemic fluorotic areas.

    J Trace Elem Med Biol 1996, 10:149-55. PubMed Abstract OpenURL

  30. Chen F, Cole P, Wen L, Mi Z, Trapido EJ: Estimates of trace element intakes in Chinese farmers.

    J Nutr 1994, 124:196-201. PubMed Abstract | Publisher Full Text OpenURL

  31. Gullberg B, Johnell O, Kanis JA: World-wide projections for hip fracture.

    Osteoporos Int 1997, 7:407-13. PubMed Abstract | Publisher Full Text OpenURL

  32. Greenspan SL, Resnick NM, Parker RA: Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.

    J Clin Endocrinol Metab 2005, 90:2762-67. PubMed Abstract | Publisher Full Text OpenURL

  33. Ravn P: Bisphosphonates for prevention of postmenopausal osteoporosis.

    Dan Med Bull 2002, 49:1-18. PubMed Abstract OpenURL

  34. Greenspan SL, Rosen HN, Parker RA: Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.

    J Clin Endocrinol Metab 2000, 85:3537-40. PubMed Abstract | Publisher Full Text OpenURL

  35. Kim MH, Bae YJ, Choi MK, Chung YS: Silicon supplementation improves the bone mineral density of calcium-deficient ovariectomized rats by reducing bone resorption.

    Biol Trace Elem Res 2009, 128:239-47. PubMed Abstract | Publisher Full Text OpenURL

  36. Seamans KM, Hill TR, Wallace JM, Horigan G, Lucey AJ, Barnes MS, et al.: Cholecalciferol supplementation throughout winter does not affect markers of bone turnover in healthy young and elderly adults.

    J Nutr 2010, 140:454-60. PubMed Abstract | Publisher Full Text OpenURL

  37. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ: Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.

    J Bone Miner Res 2004, 19:1221-30. PubMed Abstract | Publisher Full Text OpenURL